From Import to Homegrown: Vietnam’s Vaccine Scale-up and Localization Drive

Localization is not only about demand; it is also about building production capability that can serve public programs. In June 2024, Vinbiocare expanded a vaccine production facility in Hanoi, raising capacity to 200 million doses annually. The expansion is described as part of a collaboration with Arcturus Therapeutics, which provides technology for manufacturing mRNA COVID-19 vaccines. The facility is located in the Hoa Lac Hi-tech Park and is designed to bolster Vietnam’s capabilities in vaccine production, with an investment described as over $200 million. This kind of build-out supports larger procurement cycles where the state is a primary buyer for routine immunization and pandemic response campaigns.

Where Scale Meets Strategy: Demand, Hubs, and Product Mix

Reports that map vaccine value chains in Vietnam emphasize the central role of government agencies and procurement bodies in shaping demand for large-scale programs. That demand structure can reward manufacturing systems that can meet regulated standards, including GMP, and provide consistent supply for routine pediatric and adult immunization. Market segmentation also matters for scale. One market outlook notes multivalent vaccines hold a substantial market share because they offer broad coverage against multiple strains or diseases in a single dose and are favored for large-scale immunization programs, including those for diphtheria, tetanus, pertussis, and HPV. These program realities are directly tied to manufacturing choices, capacity planning, and technology investment.

Geography inside Vietnam also shapes where localization takes root. Ho Chi Minh City is described as holding a high market value because it functions as a critical hub for vaccine research and development and attracts multinational pharmaceutical companies. At the same time, the biotech market context points to the North becoming an epicenter of biotech activities, steering growth and innovation. In 2023, Vietnam’s biotech market is valued at USD 1.5 billion, with drivers that include government support for biopharmaceutical manufacturing, international partnerships, and rising demand for affordable biologic therapies. These conditions create a practical runway for manufacturers and partners who are trying to translate investment into reliable output.

Vietnam’s move from importer to producer also shows up in trade signals, but the available export details are presented with placeholder values rather than concrete totals. IndexBox reporting indicates vaccine exports from Vietnam rose strongly over time, peaking in 2025, and identifies the Lao People’s Democratic Republic as the main destination by volume, with Bangladesh also named among key destinations. The same source discusses export pricing trends, including growth in 2025 versus the prior year, but does not provide fully specified numeric price levels in the visible excerpt. Even with limited disclosed figures, the direction is clear: as domestic manufacturing expands, Vietnam is positioning for more resilient supply at home and a stronger role in regional distribution over time.